The challenge of measuring relatively weak forces between components has been addressed by a number of instrumented indentation and lateral loading devices, which all make use of probes that are brought into contact or near contact with the target surface while the normal and lateral (friction) load on and displacement of the probe are measured. With sharp enough probes, it is possible to observe oscillations in the lateral force-displacement response whose maxima and minima, respectively, coincide with the onset of slipping and attachment of the probe to the target surface and were commensurate with the interatomic spacing of the mica surface that was being probed ( 3) . The novelty of the experiment by Koren et al. lies in the use of an atomic force microscope to apply a lateral shear force to disks (mesas) of HOPG. The disks, 50 nm thick and with radii that ranged from 50 to 300 nm, were sheared along the basal plane of the graphite, about 10 nm from their bases. A classic frictional lateral load-displacement response was observed, which was largely reversible except for dynamic dissipative events that occurred during sliding. They can be seen as slight differences in the force-displacement response during sliding in opposite directions. These latter events were related to slight rotational misalignments between the graphite lattices above and below the slip plane. In addition, in a second set of experiments, when a torque was applied to the mesas, stable orientations were observed every 60°, in registration with the sixfold symmetry of the hexagonal carbon atom lattice. A third set of experiments, with a structure exhibiting mechanical bistability, demonstrated the potential to produce cell structures for memory devices that are entirely mechanical in operation. The various equilibrium states of these tiny cells could then be used as switches in such memory devices. The idea behind the method developed by Koren et al. can be illustrated more easily if we consider, for example, a toy system consisting of ping-pong balls glued together in a hexagonal pattern (close packed) in two planes that are placed on top of one another (see the figure) . The in-plane attachment is much stronger than the interaction between the planes, just as in layered, two-dimensional materials. One can imagine sliding or rotating the planes relative to one another and finding a series of equilibrium positions.
Another opportunity afforded by the experiment of Koren et al. is that it may present a close link to multiscale modeling from atomistic to continuum scales in that the interface or slip plane was free of any contamination and the geometry was relatively simple, which is not usually the case for contact pairs. Although atomistic or molecular analyses have provided insights into deformation and dissipation mechanisms and other effects that are difficult to separate out experimentally, one-to-one comparisons are limited by the high shear velocities and nanometer-scale probe tips that are currently accessible to analysis. Some progress in this direction has been provided by quartz microbalance experiments ( 4) and molecular analyses ( 5) of krypton monolayers sliding on gold, where the close agreement between simulation and experiment identified mechanisms for phononic contributions to friction. Molecular self-assembled monolayers provide another, slightly more complex avenue for linking experiments and analysis in addition to having technological relevance to MEMS. The issue of time and spatial scaling in atomistic analyses of friction between self-assembled monolayers has been identified as one of the current challenges in single asperity friction ( 6) . One possible way of addressing this issue is through hybrid analyses with schemes that combine molecular analyses with phenomenological potentials ( 7, 8) that have allowed typical sliding speeds to be accessed.
Understanding friction in layered materials
Koren et al. have come up with a novel experiment that provides a better understanding of friction in layered materials. Although graphite was the subject of this study, the extension to the plethora of twodimensional materials that are becoming available is clear. The authors have also provided much food for thought in developing potential applications of the observed phenomena to novel memory devices and machines. ■ T he development of new drugs for tuberculosis (TB) is not for the faint of heart. In addition to all the typical hurdles to developing a new antiinfective, additional complications result from the complex pathology induced by the disease. Because the bacillus is surrounded by a thick, waxy coat, hit rates in whole-cell screens are typically low; the resulting hits are typically so lipophilic that they do not offer good chemical starting points. Despite extensive research efforts, no TB drug has been developed using target-based approaches. Advances in imaging at both a macroscopic and microscopic level offer new insights and strategies for getting urgently needed new drugs to the clinic.
TB is a disease of the lungs: It is transmitted by inhalation of an aerosol droplet containing the bacterium, which implants in small alveoli and then invades and multiplies in the interstitial spaces in the lung. Here, it forms granulomas-that is, nodules of immune cells recruited as the body attempts to wall off the invading bacteria. Eventually, the granulomas undergo necrosis to form cavities and leak out into the airways, spilling bacteria into the lungs and inducing coughing to enable transmission to a new host. A single patient with TB can have dozens of individual lesions, all at different stages of maturation.
TB therapy is often very protracted. Standard medical care for pulmonary TB patients globally involves 6 months of treatment. Although full treatment is successful in 95% of patients, in reality many patients fail to complete such a long course of therapy; mobilizing the resources to ensure full compliance is nearly impossible in resource-poor countries where the disease is endemic. Shorter courses of treatment are one of the major goals of global research efforts because they would allow for more supervision, less recurrent disease, and correspondingly less opportunity for developing drug resistance.
U.S. and European regulatory bodies mandate that end points in phase 3 clinical trials of new TB drugs focus on achieving disease-free status in patients 1 year after completion of treatment. Because determining relapse-free cure requires such a long time, end points in phase 2 clinical trials focus on killing bacteria in expectorated sputum over the first few months of treatment. It has long been clear that the end points in these two different stages of clinical evaluation are not well correlated, as emphasized again recently by the failure of three large phase 3 studies that aimed to shorten the standard 6-month regimen to four months by including a fluoroquinolone as part of a four-drug regimen (1) (2) (3) . Despite achieving earlier sterilization of sputum than conventional therapy in preceding phase 2 studies and in the phase 3 trials themselves, more patients in the 4-month fluoroquinolone arms suffered relapse after treatment was discontinued. The fact that these patients were obviously not cured shows that bacteria in the sputum do not tell a complete story. Nor would one expect them to do so, given that only certain lesions produce bacteria that are represented in the airways.
Curing all patients with a shortened TB treatment regimen requires developing an understanding of what leads to a relapsedefined as recurrent disease with the same bacterial strain after apparent initial cure-in a subset of treated patients. There are two main hypotheses for why relapse occurs. One argues that relapse is due to a subset of bacteria with unique physiology (imposed by drugs, 
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